Development of novel drugs for human African trypanosomiasis

Brun, R. and Don, R. and Jacobs, R. T. and Wang, M. Z. and Barrett, M. P.. (2011) Development of novel drugs for human African trypanosomiasis. Future microbiology, Vol. 6. pp. 677-691.

Full text not available from this repository.

Official URL: http://edoc.unibas.ch/dok/A6002164

Downloads: Statistics Overview


Human African trypanosomiasis (HAT) or 'sleeping sickness' is a neglected tropical disease caused by the parasite Trypanosoma brucei. Novel models for funding pharmaceutical development against HAT are beginning to yield results. The Drugs for Neglected Diseases initiative (DNDi) rediscovered a nitroimidazole, fexinidazole, which is currently in Phase I clinical trials. Novel benzoxaboroles, discovered by Anacor, Scynexis and DNDi, have good pharmacokinetic properties in plasma and in the brain and are curative in a murine model of stage two HAT with brain infection. The Consortium for Parasitic Drug Development (CPDD) has identified a series of dicationic compounds that can cure a monkey model of stage two HAT. With other screening programs yielding hits, the pipeline for new HAT drugs might finally begin to fill
Faculties and Departments:09 Associated Institutions > Swiss Tropical and Public Health Institute (Swiss TPH) > Department of Medical Parasitology and Infection Biology (MPI) > Parasite Chemotherapy (Mäser)
UniBasel Contributors:Brun, Reto
Item Type:Article, refereed
Article Subtype:Research Article
Bibsysno:Link to catalogue
Publisher:Future Medicine Ltd
Note:Publication type according to Uni Basel Research Database: Journal article
Related URLs:
Identification Number:
Last Modified:11 Oct 2012 15:32
Deposited On:11 Oct 2012 15:30

Repository Staff Only: item control page